Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

• Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:
• Absolute neutrophil count (ANC) ≥ 1,000/µL
• Platelet count ≥ 75,000/µL
• Absolute lymphocyte count ≥ 100/µL
• Creatinine clearance above limits set in the protocol for each cohort
• Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram
• Baseline oxygen saturation > 92% on room air and no clinically significant pleural effusion Key

Exclusion Criteria

• Plasma cell leukemia
• Non-secretory multiple myeloma
• History of Central nervous system (CNS) involvement by multiple myeloma
• Prior CAR therapy or other genetically modified T cells
• Inadequate washout from prior therapy
• Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
• History of active autoimmune disease
• History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
• Recent history of other (non multiple myeloma) cancer
• Active viral, fungal, bacterial or other infection Note: Other protocol defined Inclusion/Exclusion criteria may apply